Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

Summary

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor. The aim of the study io evaluate the utility of Ezetimibe in combination with pegylated interferon in patients with chronic HDV infection.

Timeline

Start

2016-01

Primary completion

2016-12

Completion

2017-06

Drugs

Indications